Skip to Content

H. Lundbeck A/S (DK) - Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued

COPENHAGEN, July 30, 2009--H. Lundbeck A/S (Lundbeck) today announced the joint decision with its partner Solvay Pharmaceuticals, B.V. (Solvay) to stop all joint R&D activities for Solvay's compound bifeprunox in development for maintenance treatment of schizophrenia.

The companies made this decision after evaluating the recent results from an interim analysis of pooled data intended for a possible extension of the ongoing clinical phase III trial programme. Efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia. Therefore, Lundbeck and Solvay judge that it would be futile to continue the studies.

The content of this release will have no influence on the Lundbeck Group's financial result for 2009.

About bifeprunox Bifeprunox, a partial dopamine and serotonin 5-HT1A agonist designed to stabilize dopamine function in the brain, has been studied in more than 2,500 patients with schizophrenia in 14 efficacy and safety studies conducted throughout the world. Solvay is the originator of the compound.

Lundbeck contacts





Jacob Tolstrup

Mads Kronborg

Director, IR & Communication

Media Relations

+45 36 43 30 79

+45 36 43 28 51



Palle Holm Olesen


Head of Investor Relations


+45 36 43 24 26




Magnus Thorstholm Jensen


Investor Relations Officer


+45 36 43 38 16



About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit

Posted: July 2009